Cambridge Biotech Firm Raises $25M for AI Drug Discovery
· Technology · The Times, Business Standard
A Cambridge-based biotechnology startup has secured $25 million in new funding to expand its artificial intelligence platform for pharmaceutical research. The capital injection aims to accelerate target identification and drug development pipelines. Industry investment in AI-driven healthcare solutions has surged amid growing demand for faster therapeutic discovery. The company plans to scale its technical infrastructure and expand research partnerships.
Why it matters
Increased venture capital funding in AI biotech accelerates the integration of machine learning into pharmaceutical research, potentially reducing drug development timelines.
Read the original report — The Times
Join us on Telegram
Breaking news the moment it lands. At 10,000 members we ship the Android app.